Abstract
DNA methylation is an epigenetic event involved in a variety array of processes that may be the foundation of genetic phenomena and diseases. DNA methyltransferase is a key enzyme for cytosine methylation in DNA, and can be divided into two functional families (Dnmt1 and Dnmt3) in mammals. All mammalian DNA methyltransferases are encoded by their own single gene, and consisted of catalytic and regulatory regions (except Dnmt2). Via interactions between functional domains in the regulatory or catalytic regions and other adaptors or cofactors, DNA methyltransferases can be localized at selective areas (specific DNA/nucleotide sequence) and linked to specific chromosome status (euchromatin/ heterochromatin, various histone modification status). With assistance from UHRF1 and Dnmt3L or other factors in Dnmt1 and Dnmt3a/Dnmt3b, mammalian DNA methyltransferases can be recruited, and then specifically bind to hemimethylated and unmethylated double-stranded DNA sequence to maintain and de novo setup patterns for DNA methylation. Complicated enzymatic steps catalyzed by DNA methyltransferases include methyl group transferred from cofactor Ado-Met to C5 position of the flipped-out cytosine in targeted DNA duplex. In the light of the fact that different DNA methyltransferases are divergent in both structures and functions, and use unique reprogrammed or distorted routines in development of diseases, design of new drugs targeting specific mammalian DNA methyltransferases or their adaptors in the control of key steps in either maintenance or de novo DNA methylation processes will contribute to individually treating diseases related to DNA methyltransferases.
Keywords: DNA methyltransferase, epigenetics, enzyme catalysis, protein-DNA interactions, DNA MTase, replication- foci targeting, RFT, targeting sequence, TS, methyl-CpG binding protein-2, MeCP2, methyl-CpG binding domain protein, MBD2, MBD3, HDAC1, histone deacetylase-1, HDAC2, H3-K9 methyltransferase, Suv39h1, HP1b, DNMT3A2, ATRX, alpha-thalassemia and mental retardation on X chromosome, TRDMT1, tRNA aspartic acid methyltransferase 1, S-adenosyl-L-homocysteine, UHRF1
Current Medicinal Chemistry
Title: Molecular and Enzymatic Profiles of Mammalian DNA Methyltransferases: Structures and Targets for Drugs
Volume: 17 Issue: 33
Author(s): F. Xu, C. Mao, Y. Ding, C. Rui, L. Wu, A. Shi, H. Zhang, L. Zhang and Z. Xu
Affiliation:
Keywords: DNA methyltransferase, epigenetics, enzyme catalysis, protein-DNA interactions, DNA MTase, replication- foci targeting, RFT, targeting sequence, TS, methyl-CpG binding protein-2, MeCP2, methyl-CpG binding domain protein, MBD2, MBD3, HDAC1, histone deacetylase-1, HDAC2, H3-K9 methyltransferase, Suv39h1, HP1b, DNMT3A2, ATRX, alpha-thalassemia and mental retardation on X chromosome, TRDMT1, tRNA aspartic acid methyltransferase 1, S-adenosyl-L-homocysteine, UHRF1
Abstract: DNA methylation is an epigenetic event involved in a variety array of processes that may be the foundation of genetic phenomena and diseases. DNA methyltransferase is a key enzyme for cytosine methylation in DNA, and can be divided into two functional families (Dnmt1 and Dnmt3) in mammals. All mammalian DNA methyltransferases are encoded by their own single gene, and consisted of catalytic and regulatory regions (except Dnmt2). Via interactions between functional domains in the regulatory or catalytic regions and other adaptors or cofactors, DNA methyltransferases can be localized at selective areas (specific DNA/nucleotide sequence) and linked to specific chromosome status (euchromatin/ heterochromatin, various histone modification status). With assistance from UHRF1 and Dnmt3L or other factors in Dnmt1 and Dnmt3a/Dnmt3b, mammalian DNA methyltransferases can be recruited, and then specifically bind to hemimethylated and unmethylated double-stranded DNA sequence to maintain and de novo setup patterns for DNA methylation. Complicated enzymatic steps catalyzed by DNA methyltransferases include methyl group transferred from cofactor Ado-Met to C5 position of the flipped-out cytosine in targeted DNA duplex. In the light of the fact that different DNA methyltransferases are divergent in both structures and functions, and use unique reprogrammed or distorted routines in development of diseases, design of new drugs targeting specific mammalian DNA methyltransferases or their adaptors in the control of key steps in either maintenance or de novo DNA methylation processes will contribute to individually treating diseases related to DNA methyltransferases.
Export Options
About this article
Cite this article as:
Xu F., Mao C., Ding Y., Rui C., Wu L., Shi A., Zhang H., Zhang L. and Xu Z., Molecular and Enzymatic Profiles of Mammalian DNA Methyltransferases: Structures and Targets for Drugs, Current Medicinal Chemistry 2010; 17 (33) . https://dx.doi.org/10.2174/092986710793205372
DOI https://dx.doi.org/10.2174/092986710793205372 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Regulators of Stem Cells Proliferation in Tissue Regeneration
Current Stem Cell Research & Therapy Local Gene Delivery for Cancer Therapy
Current Gene Therapy NO to Breast: When, Why and Why Not?
Current Pharmaceutical Design Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma
Current Cancer Drug Targets Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Subject index to volume 3
Current Molecular Medicine Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Current Cancer Therapy Reviews